Clinical trial registry record

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 30, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05283486
Last registry update
October 30, 2023
Status
Completed
Phase
Phase 2
Sponsor
TNF Pharmaceuticals, Inc.
Enrollment
40
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
40
Population
ALL · 65 Years to 99 Years
Duration
2022-02-01 to 2023-06-07
Intervention
MYMD-1 600MG; MYMD-1 750mg; MYMD-1 900mg; MYMD-1 1050mg; placebo 600mg; placebo 750mg; placebo 900mg; placebo 1050mg
Comparator
Cohort 1: Placebo 600mg; Cohort 2: Placebo 750mg; Cohort 3: Placebo 900mg; Cohort 4: MYMD1 1050mg; Cohort 4: Placebo group 1050mg
Outcomes measured
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Screening; Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Day 1; Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Day 7; Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Day 14; Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Day 21; Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1 — Day 28; To evaluate the PK of oral doses of MYMD1 capsules — Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8,…; To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 1 (predose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 1 (0-4 hrs post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 1 (4-8 hrs post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 1(8-24hrs post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 7 (predose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 7 (0-4 hours post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 7 (4-8 hours post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 7 (8-24hrs post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 14 (predose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 14 (0-4 hours post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 14 (4-8 hours post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 14 (8-24 hours post dose); To evaluate the PK (urine) of oral doses of MYMD1 capsules — Day 21 (predose)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Chronic inflammation · 100%Title contains controlled term: chronic inflammation. Abstract contains controlled term: chronic inflammation. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.
  • Sarcopenia · 100%Title contains controlled term: sarcopenia. Abstract contains controlled term: sarcopenia. Source terminology contains: sarcopenia. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

chronic inflammationsarcopenia
Open primary sourceExport JSON